Start Date: ,
End Date: ,
Click here to access the article.
Section snippet
Anticoagulation for Subclinical Atrial Fibrillation: Recently, the ARTESIA study addressed this question in a randomized trial of 4,012 patients with subclinical atrial fibrillation identified by an implanted device, and CHA2DS2-VASc score of at least 3.4 Subclinical atrial fibrillation was defined as at least 1 episode lasting 6 minutes up to 24 hours.4 Patients were allocated randomly to apixaban or aspirin, and over a median of 3.5 years, apixaban significantly decreased stroke and other systemic embolic phenomena compared to aspirin (0.78% v . . .